News coverage about Becton, Dickinson and (NYSE:BDX) has been trending positive on Thursday, according to Accern. The research firm identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Becton, Dickinson and earned a daily sentiment score of 0.28 on Accern’s scale. Accern also assigned headlines about the medical instruments supplier an impact score of 46.784656099112 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

These are some of the news headlines that may have effected Accern Sentiment Analysis’s scoring:

A number of analysts have recently weighed in on the stock. Stifel Nicolaus reiterated a “buy” rating on shares of Becton, Dickinson and in a research note on Wednesday, August 9th. Cowen and Company reissued a “buy” rating and set a $230.00 price target on shares of Becton, Dickinson and in a report on Monday, August 14th. Barclays PLC reissued an “equal weight” rating and set a $210.00 price target (up from $205.00) on shares of Becton, Dickinson and in a report on Thursday, August 10th. BidaskClub raised shares of Becton, Dickinson and from a “hold” rating to a “buy” rating in a report on Monday, August 14th. Finally, Royal Bank Of Canada reissued a “sector perform” rating and set a $230.00 price target (up from $210.00) on shares of Becton, Dickinson and in a report on Friday, November 3rd. Five investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $213.47.

Shares of Becton, Dickinson and (NYSE BDX) traded down $1.36 on Thursday, hitting $219.10. 811,500 shares of the company’s stock were exchanged, compared to its average volume of 1,329,950. Becton, Dickinson and has a 1-year low of $161.29 and a 1-year high of $225.23. The firm has a market capitalization of $50,360.00, a PE ratio of 23.23, a PEG ratio of 1.73 and a beta of 1.04. The company has a current ratio of 5.56, a quick ratio of 5.01 and a debt-to-equity ratio of 1.48.

Becton, Dickinson and (NYSE:BDX) last announced its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share for the quarter, beating analysts’ consensus estimates of $2.37 by $0.03. Becton, Dickinson and had a net margin of 8.52% and a return on equity of 22.51%. The business had revenue of $3.17 billion during the quarter, compared to analysts’ expectations of $3.14 billion. During the same period last year, the business earned $2.12 earnings per share. The business’s revenue for the quarter was down 2.0% on a year-over-year basis. equities analysts forecast that Becton, Dickinson and will post 10.63 earnings per share for the current year.

In other news, EVP Linda M. Tharby sold 4,695 shares of the firm’s stock in a transaction that occurred on Tuesday, August 22nd. The shares were sold at an average price of $200.48, for a total value of $941,253.60. Following the completion of the transaction, the executive vice president now owns 18,670 shares of the company’s stock, valued at $3,742,961.60. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Gary M. Cohen sold 15,044 shares of the firm’s stock in a transaction that occurred on Tuesday, August 22nd. The shares were sold at an average price of $200.43, for a total transaction of $3,015,268.92. Following the completion of the transaction, the insider now directly owns 95,270 shares of the company’s stock, valued at approximately $19,094,966.10. The disclosure for this sale can be found here. In the last three months, insiders sold 47,038 shares of company stock valued at $9,480,225. Insiders own 1.40% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Favorable Media Coverage Somewhat Unlikely to Affect Becton, Dickinson and (BDX) Stock Price” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/11/16/favorable-media-coverage-somewhat-unlikely-to-affect-becton-dickinson-and-bdx-stock-price.html.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Insider Buying and Selling by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Stock Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related stocks with our FREE daily email newsletter.